Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of ATL-DC-101 autologous dendritic cell vaccine for adult T-cell leukemia/lymphoma
jRCT2073210013Phase 2Active, not recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Apr 2021
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of AV-GBM-1 in adult T-cell leukemia-lymphoma (ATLL) (2 arms), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Progression-free survival. Started Apr 2021; status: active, not recruiting.
02
Drugs
AV-GBM-1
03
Conditions
adult T-cell leukemia-lymphoma (ATLL)
Beyond the preview
Go deeper on jRCT2073210013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2073210013.